CusterJWRauRE, eds. Johns Hopkins: The Harriet Lane Handbook. 18th ed.Philadelphia, PA: Elsevier Mosby; 2009.
2.
RossoDARoyAZelazkoMBraierJL. Prognostic value of soluble interleukin 2 receptor levels in Langerhans cell histiocytosis. Br J Haematol. 2002;117:54-58.
3.
WeizterSEgelerRM, eds. Histiocytic Disorders of Children and Adults. Cambridge, England: Cambridge University Press; 2005.
4.
YousemSAColbyTVChenYYChenWGWeissLM. Pulmonary Langerhans’ cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol. 2001;25: 630-636.
5.
McClainKLLaudPWuWSPollackMS. Langerhans cell histiocytosis patients have HLA Cw7 and DR4 phenotypes associated with specific clinical presentations and no increased frequency in polymorphisms of the tumor necrosis factor alpha promoter. Med Pediatr Oncol. 2003;41:502-507.
6.
GroisNGFavaraBEMostbeckGHPrayerD.Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:287-305.
7.
MaghnieMCosiGGenoveseE. Central diabetes insipidus in children and young adults. N Engl J Med. 2000;343:998-1007.
8.
FleischerABJr. Diagnosis and management of common dermatoses in children: atopic, seborrheic, and contact dermatitis. Clin Pediatr (Phila). 2008;47:332-346.
9.
DehnerLP. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry. Am J Surg Pathol. 2005;29:21-28.
10.
FreyerDRKennedyRBostromBCKohutGDehnerLP. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr. 1996;129:227-237.
11.
Veyssier-BelotCCacoubPCaparros-LefebvreD. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996;75:157-169.
WeitzmanSBraierJDonadieuJ. 2′-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer. 2009;53: 1271-1276.
14.
AkkariVDonadieuJPiguetC. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant. 2003;31:1097-1103.
15.
SteinerMMatthes-MartinSAttarbaschiA. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005;36:215-225.